Overview

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

Status:
Completed
Trial end date:
2021-02-04
Target enrollment:
Participant gender:
Summary
This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and HIV-uninfected individuals.
Phase:
Phase 1
Details
Lead Sponsor:
Rockefeller University
Treatments:
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins